13F filer · CIK 2077247
Trails Edge Capital Partners, LP
ATLANTA, GA · filing since Q4 2025 · last filing Aug 14, 2026
Reported value
$629.9M
+$193.4M vs prior
Positions
35
New / sold out
13 / 5
Added / reduced
10 / 7
Turnover
30.4%
buys $278.1M · sells $162.3M
Top-10 weight
50.3%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | FIRST TRACKS BIOTHERAPEUTICS | +1,514,000 | – | +$30.5M |
| New | BIOMARIN PHARMACEUTICAL INC | +512,000 | – | +$29.3M |
| New | INSMED INC | +230,331 | – | +$24.6M |
| New | KAILERA THERAPEUTICS INC | +984,786 | – | +$21.7M |
| New | INCYTE CORP | +155,000 | – | +$17.6M |
| Added | DESIGN THERAPEUTICS INC | +1,149,269 | +134.9% | +$16.6M |
| New | AVALO THERAPEUTICS INC | +891,881 | – | +$16.5M |
| New | MOONLAKE IMMUNOTHERAPEUTICS | +750,000 | – | +$14.6M |
| Added | 4D MOLECULAR THERAPEUTICS IN | +925,000 | +71.0% | +$12.3M |
| Added | IMMUNOCORE HLDGS PLC | +380,637 | +55.8% | +$12.1M |
13 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | VAXCYTE INC | -662,470 | -100.0% | $-38.5M |
| Sold out | DEFINIUM THERAPEUTICS INC | -1,738,110 | -100.0% | $-32.9M |
| Reduced | REVOLUTION MEDICINES INC | -129,250 | -52.8% | $-24.2M |
| Sold out | ARCUS BIOSCIENCES INC | -1,047,935 | -100.0% | $-22.6M |
| Reduced | MIRUM PHARMACEUTICALS INC | -110,000 | -33.0% | $-12.9M |
| Sold out | XENON PHARMACEUTICALS INCPUT | -200,000 | -100.0% | $-11.6M |
| Sold out | IMMUNOVANT INC | -414,054 | -100.0% | $-10.3M |
| Reduced | NURIX THERAPEUTICS INC | -170,000 | -9.8% | $-4.1M |
| Reduced | NEUROGENE INC | -67,902 | -8.7% | $-2.1M |
| Reduced | VTV THERAPEUTICS INC | -54,386 | -39.0% | $-2.0M |
2 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | LB PHARMACEUTICALS INCCOM SHS | 1,523,022 | $49.4M | 7.85% |
| 2 | NURIX THERAPEUTICS INCCOM | 1,573,220 | $38.2M | 6.06% |
| 3 | IMMUNOCORE HLDGS PLCADS | 1,063,234 | $33.8M | 5.36% |
| 4 | FIRST TRACKS BIOTHERAPEUTICSORD SHS | 1,514,000 | $30.5M | 4.84% |
| 5 | 4D MOLECULAR THERAPEUTICS INCOM | 2,227,917 | $29.6M | 4.70% |
| 6 | BIOMARIN PHARMACEUTICAL INCCOM | 512,000 | $29.3M | 4.65% |
| 7 | DESIGN THERAPEUTICS INCCOM | 2,001,282 | $29.0M | 4.60% |
| 8 | XENON PHARMACEUTICALS INCCOM | 440,000 | $26.6M | 4.22% |
| 9 | MIRUM PHARMACEUTICALS INCCOM | 223,312 | $26.1M | 4.15% |
| 10 | INSMED INCCOM PAR $.01 | 230,331 | $24.6M | 3.90% |
25 more rows. Subscribe for $29/month to see every row, download the data and use the API.